Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 3/20 | 0.34 |
| ▸ | NAAA | Q02083 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | KDM4A | O75164 | 1/20 | 0.34 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.34 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7224595 | 0.98 | RARB (0.40) | RARBLMNABLMNAAAKDM4C | |
| SCHEMBL6477990 | 0.98 | RARB (0.40) | RARBLMNABLMNAAAKDM4C | |
| SCHEMBL7224844 | 0.98 | RARB (0.40) | RARBLMNABLMNAAAKDM4C | |
| SCHEMBL7219284 | 0.98 | RARB (0.40) | RARBLMNABLMNAAAKDM4C | |
| SCHEMBL9278406 | 0.98 | RARB (0.40) | RARBLMNABLMNAAAKDM4C | |
| SCHEMBL4675873 | 0.93 | BLM (0.39) | RARBLMNABLMPTPN1CA1 | |
| SCHEMBL30849949 | 0.90 | LMNA (0.52) | RARBLMNABLMPTPN1NAAA | |
| SCHEMBL6476866 | 0.90 | LMNA (0.52) | RARBLMNABLMPTPN1NAAA | |
| SCHEMBL6477852 | 0.90 | LMNA (0.52) | RARBLMNABLMPTPN1NAAA | |
| SCHEMBL6472477 | 0.87 | FAAH (0.41) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3839028-B1 | CLEANING PRODUCT | PROCTER & GAMBLE (US) | 2025-01-15 | — | — | EP | disclosed |
| US-20240239786-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF CANCER | YALE UNIVERSITY | 2024-07-18 | — | — | US | disclosed |
| EP-4386075-A2 | CLEANING PRODUCT | The Procter & Gamble Company (US) | 2024-06-19 | — | — | EP | disclosed |
| US-11911751-B2 | Catalyst compositions for hydroformylation and methods of use thereof | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2024-02-27 | — | — | US | disclosed |
| US-11873312-B2 | Transcriptome in vivo analysis (TIVA) and transcriptome in situ analysis (TISA) | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2024-01-16 | — | — | US | disclosed |
| US-11834629-B2 | Cleaning product | THE PROCTER & GAMBLE COMPANY (US) | 2023-12-05 | — | — | US | disclosed |
| US-11834627-B2 | Cleaning product | THE PROCTER & GAMBLE COMPANY (US) | 2023-12-05 | — | — | US | disclosed |
| EP-4124651-B1 | CLEANING PRODUCT | PROCTER & GAMBLE (US) | 2023-11-29 | — | — | EP | disclosed |
| US-11787794-B2 | Aminothiazole compounds and methods using same | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2023-10-17 | — | — | US | disclosed |
| US-11753604-B2 | Cleaning product | THE PROCTER & GAMBLE COMPANY (US) | 2023-09-12 | — | — | US | disclosed |
| US-20120283296-A1 | PYRROLOPYRAZOLES FOR TREATING CNS DISORDERS | AFRAXIS, INC. (US) | 2012-11-08 | — | — | US | disclosed |
| US-20120270866-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS INC. (US) | 2012-10-25 | — | — | US | disclosed |
| US-20120184547-A1 | METHODS FOR TREATING SCHIZOPHRENIA | AFRAXIS, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120157399-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF OBESITY AND DIABETES | SATIOGEN PHARMACEUTICALS, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120046283-A1 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | AFRAXIS INC. (US) | 2012-02-23 | — | — | US | disclosed |
| US-20120028981-A1 | Kinase Knockdown Via Electrophilically Enhanced Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2012-02-02 | — | — | US | disclosed |
| US-20110294833-A1 | Methods for Healthy Aging | SCRIPPS HEALTH (US) | 2011-12-01 | — | — | US | disclosed |
| US-20110218210-A1 | COMPOUNDS FOR TREATING ABNORMAL CELLULAR PROLIFERATION | Taiga Biotechnologies (US) | 2011-09-08 | — | — | US | disclosed |
| US-6667285-B1 | Branched-chain carboxylic acid monoalkyl ester with outstanding hydrolytic stability | NEW JAPAN CHEMICAL CO., LTD. (JP) | 2003-12-23 | — | — | US | disclosed |
| EP-1225213-A1 | LUBRICATING OIL FOR REFRIGERATOR, HYDRAULIC FLUID COMPOSITION FOR REFRIGERATOR AND METHOD FOR LUBRICATION OF REFRIGERATOR | NEW JAPAN CHEMICAL CO.,LTD. (JP) | 2002-07-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218210-A1 | COMPOUNDS FOR TREATING ABNORMAL CELLULAR PROLIFERATION | MKI67, PCNA, CCNC | RARB 819/4885LMNA 1353/4885BLM 1065/4885 |
| US-11787794-B2 | Aminothiazole compounds and methods using same | BRCA1, ALDH7A1, MGMT | RARB 3466/4885LMNA 3056/4885BLM 1796/4885 |
| US-20120028981-A1 | Kinase Knockdown Via Electrophilically Enhanced Inhibitors | MAP3K20, MAP3K6, MAP3K19 | RARB 2979/4885LMNA 3613/4885BLM 2706/4885 |
| US-20120157399-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF OBESITY AND DIABETES | SLC10A1, SLC10A2, ABCB11 | RARB 504/4885LMNA 4642/4885BLM 3365/4885 |
| US-11873312-B2 | Transcriptome in vivo analysis (TIVA) and transcriptome in situ analysis (TISA) | RNMT, RNGTT, NSUN2 | RARB 270/4885LMNA 1554/4885BLM 1675/4885 |
| US-20110294833-A1 | Methods for Healthy Aging | HTT, TELO2, GLA | RARB 3716/4885LMNA 495/4885BLM 2567/4885 |
| US-20120270866-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | PAK2, PAK6, PAK5 | RARB 3432/4885LMNA 4236/4885BLM 3249/4885 |
| US-20120283296-A1 | PYRROLOPYRAZOLES FOR TREATING CNS DISORDERS | PAK2, PAK3, PAK5 | RARB 3843/4885LMNA 4348/4885BLM 4461/4885 |
| US-20240239786-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF CANCER | BRCA1, RAD51, PARP3 | RARB 737/4885LMNA 678/4885BLM 19/4885 |
| US-20120046283-A1 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | PAK2, PAK5, PAK6 | RARB 2702/4885LMNA 4498/4885BLM 3524/4885 |
| US-20120184547-A1 | METHODS FOR TREATING SCHIZOPHRENIA | PAK2, PAK3, PAK4 | RARB 937/4885LMNA 4009/4885BLM 4601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.